Dr. Jay S. Dalal, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 557
Licensed in Illinois since 2008, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036120228 (first issued 2008; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uchicago Medicine Adventhealth Hinsdale Hinsdale, IL
- Uchicago Medicine Adventhealth La Grange La Grange, IL
- Uchicago Medicine Adventhealth Bolingbrook Bolingbrook, IL
- Uchicago Medicine Adventhealth Glenoaks Glendale Heights, IL
Medical groups
- Ahp Specialty Care Nfp (31 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 557
- Services billed
- 2,671
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 591 | 260 |
| Established patient office or other outpatient visit, 40-54 minutes | 435 | 167 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 172 | 85 |
| Established patient office or other outpatient visit, 20-29 minutes | 92 | 84 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 74 | 74 |
| New patient office or other outpatient visit, 60-74 minutes | 56 | 56 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 40 | 28 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Hinsdale, IL | 170 |
| Anastrozole Other prescribers in Hinsdale, IL | 98 |
| Prochlorperazine Maleate Other prescribers in Hinsdale, IL | 90 |
| Xarelto (rivaroxaban) Other prescribers in Hinsdale, IL | 80 |
| Ondansetron Hcl Other prescribers in Hinsdale, IL | 71 |
| Hydroxyurea Other prescribers in Hinsdale, IL | 53 |
| Acyclovir Other prescribers in Hinsdale, IL | 44 |
| Prednisone Other prescribers in Hinsdale, IL | 43 |
| Letrozole Other prescribers in Hinsdale, IL | 42 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Hinsdale, IL | 41 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 31 payments worth $3,207 in total to this clinician.
| Janssen Biotech, Inc. | $2,574 |
|---|---|
| Incyte Corporation | $147 |
| Genentech USA, Inc. | $101 |
| Jazz Pharmaceuticals Inc. | $60.62 |
| AstraZeneca Pharmaceuticals LP | $53.36 |
| Pfizer Inc. | $51.78 |
| Novartis Pharmaceuticals Corporation | $44.66 |
| Daiichi Sankyo Inc. | $28.73 |
| Consulting Fee | $2,220 |
|---|---|
| Food and Beverage | $815 |
| Education | $116 |
| Travel and Lodging | $56.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jun 11, 2025 | Consulting Fee TECVAYLI · Oncology | $2,220 |
| Incyte Corporation Sep 1, 2025 | Education | $99.99 |
| Janssen Biotech, Inc. Jun 11, 2025 | Travel and Lodging TECVAYLI · Oncology · travel to ROSEMONT, IL · in-kind | $35.00 |
| Janssen Biotech, Inc. Jun 11, 2025 | Travel and Lodging TECVAYLI · Oncology · travel to ROSEMONT, IL | $21.00 |
| Legend Biotech USA Inc. Sep 11, 2025 | Education CARVYKTI · Oncology · in-kind | $15.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $11,140 in research payments for these studies, mostly to the institutions running them.
- Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
E.r. Squibb & Sons, L.l.c. · Completed · NCT01996865
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.